Sustained reduction in antimicrobial use and decrease in methicillin-resistant Staphylococcus aureus and Clostridium difficile infections following implementation of an electronic medical record at a tertiary-care teaching hospital

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 1, 2011, Pages 205-209

  Cook, Paul P ^a   Rizzo, Shemra ^b   Gooch, Michael ^c   Jordan, Michelle ^c   Fang, Xiangming ^d   Hudson, Suzanne ^d  

^a EAST CAROLINA UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PITT COUNTY MEMORIAL HOSPITAL   (United States)

^d EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Antibiotic management; Antibiotic resistance; Nosocomial infections

Indexed keywords

AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; AZTREONAM; CEFACLOR; CEFADROXIL; CEFALEXIN; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; DAPTOMYCIN; DORIPENEM; DOXYCYCLINE; ERTAPENEM; ERYTHROMYCIN; GENTAMICIN; SULTAMICILLIN; UNINDEXED DRUG;

ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; ELECTRONIC MEDICAL RECORD; HOSPITAL INFECTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; TEACHING HOSPITAL; TERTIARY HEALTH CARE;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; DRUG UTILIZATION; ELECTRONIC HEALTH RECORDS; HOSPITALS, TEACHING; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PREVALENCE; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS;

EID: 78650372055     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq404     Document Type: Article

References (25)

1. MacDougall C, Polk RE. Antimicrobial stewardship programs in healthcare systems. Clin Microbiol Rev 2005; 18: 638-56.
2. Gould IM. Antibiotic policies to control hospital-acquired infection. J Antimicrob Chemother 2008; 61: 763-65.
3. Dellit TH, Owens RC, McGowan JE Jr et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44: 159-77.
4. Aldeyab MA, Monnet DL, Lopez-Lozano JM et al. Modelling the impact of antibiotic use and infection control practices on the incidence of hospital-acquired methicillin-resistant Staphylococcus aureus: a time-series analysis. J Antimicrob Chemother 2008; 62: 593-600.
5. Vernaz N, Sax H, Pittet D et al. Temporal effects of antibiotic use and hand rub consumption on the incidence of MRSA and Clostridium difficile. J Antimicrob Chemother 2008; 62: 601-7.
6. Muller A, Mauny F, Talon D et al. Effect of individual- and group-level antibiotic exposure on MRSA isolation: a multilevel analysis. J Antimicrob Chemother 2006; 58: 878-81.
7. Dancer SJ. The effect of antibiotics on methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2008; 61: 246-53.
8. Owens RC, Donskey CJ, Gaynes RP et al. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008; 46 Suppl 1: S19-31.
9. Cook PP, Catrou PG, Christie JD et al. Reduction in broad-spectrum antimicrobial use associated with no improvement in hospital antibiogram. J Antimicrob Chemother 2004; 53: 853-9.
10. Buising KL, Thursky KA, Robertson MB et al. Electronic antibiotic stewardship-reduced consumption of broad-spectrum antibiotics using a computerized antimicrobial approval system in a hospital setting. J Antimicrob Chemother 2008; 62: 608-16.
11. Lesprit P, Duong T, Girou E et al. Impact of a computer-generated alert system prompting review of antibiotic use in hospitals. J Antimicrob Chemother 2009; 63: 1058-63.
12. Weber SG, Gold HS, Hooper DC et al. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003; 9: 1415-22.
13. Charbonneau P, Parienti J, Thibon P et al. Fluoroquinolone use and methicillin-resistant Staphylococcus aureus isolation rates in hospitalized patients: a quasi experimental study. Clin Infect Dis 2006; 42: 778-84.
14. Pepin J, Saheb N, Coulombe MA et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41: 1254-60.
15. Cook PP, Catrou P, Gooch M et al. Effect of reduction in ciprofloxacin use on prevalence of methicillin-resistant Staphylococcus aureus rates within individual units of a tertiary care hospital. J Hosp Infect 2006; 64: 348-51.
16. Muto CA, Pokrywka M, Shutt K et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005; 26: 273-80.
17. Dial S, Alrasadi K, Manoukian C et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004; 171: 33-8.
18. Bartlett JG. Antibiotic-associated diarrhea. N Engl J Med 2002; 346: 334-9.
19. Kyne L, Sougioultzis S, McFarland LV et al. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epidemiol 2002; 23: 653-9.
20. Cunningham R, Dale B, Undy B et al. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003; 54: 243-5.
21. Merrer J, Santoli F, Appere de Vecchi C et al. "Colonization pressure" and risk of acquisition of methicillin-resistant Staphylococcus aureus in a medical intensive care unit. Infect Control Hosp Epidemiol 2000; 21: 718-23.
22. Muto CA, Jernigan JA, Ostrowsky BE et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol 2003; 24: 362-86.
23. Kyne L, Hamel MB, Polavaram R et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002; 34: 346-53.
24. O'Brien JA, Lahue BJ, Caro JJ et al. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 2007; 28: 1219-27.
25. Dubberke ER, Reske KA, Olsen MA et al. Short and long term attributable cost of Clostridium difficile-associated disease in non-surgical patients. Clin Infect Dis 2008; 46: 497-50.